Shots:

• The company’s Tecentriq SC formulation has received marketing authorization for all the indicated cancers of Tecentriq IV. The SC injection will reduce the treatment time from ~30-60mins., when administered IV, to ~7mins.
• The approval was based on the data from the P-IB/III (IMscin001) trial investigating the safety, efficacy and PK of Tecentriq SC vs Tecentriq IV for patients (n=371) with previously treated locally advanced or metastatic NSCLC who failed on prior Pt therapy
• The trial results showed that the ORR, PFS, OS and DoR were the same in the SC vs IV treatment arms with a consistent safety and known profile of Tecentriq IV

Ref: Roche | Image: Roche

Related News:- Roche received the EU’s CHMP Positive Opinion for subcutaneous injection of Tecentriq to treat multiple types of cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com